GB2376884A - Helping smokers stop - Google Patents

Helping smokers stop Download PDF

Info

Publication number
GB2376884A
GB2376884A GB0115566A GB0115566A GB2376884A GB 2376884 A GB2376884 A GB 2376884A GB 0115566 A GB0115566 A GB 0115566A GB 0115566 A GB0115566 A GB 0115566A GB 2376884 A GB2376884 A GB 2376884A
Authority
GB
United Kingdom
Prior art keywords
nicotine
nrt
smoking
provision
quit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0115566A
Other versions
GB0115566D0 (en
Inventor
Peter Hajek
Robert West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0115566A priority Critical patent/GB2376884A/en
Publication of GB0115566D0 publication Critical patent/GB0115566D0/en
Publication of GB2376884A publication Critical patent/GB2376884A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Abstract

The present invention concerns a new way of using nicotine replacement treatment to enhance its efficacy in treating patients for nicotine and tobacco addiction and for alleviating nicotine withdrawal. The invention includes providing nicotine replacement treatment in one or more forms for a period of time prior to cessation of smoking to de-condition the link between smoking behaviour and its pharmacological reinforcement, and to habituate the user to the nicotine replacement products. After stopping smoking, nicotine replacement treatment is used in the usual way.

Description

<Desc/Clms Page number 1>
HELPING SMOKERS STOP The invention relates to a novel use of the nicotine replacement treatment to enhance its efficacy in treating patients for nicotine and tobacco addiction and for alleviating nicotine withdrawal. The invention includes providing nicotine replacement treatment in one or more forms for a period of time prior to cessation of smoking to de-condition the link between smoking behaviour and its pharmacological reinforcement, and to habituate the user to the nicotine replacement products. After stopping smoking, nicotine replacement treatment is used in the usual way.
Nicotine replacement treatment (NRT) IS a smoking cessation method with limited but proven efficacy help (West, R., McNeill, A. , & Raw, M. (2000). National smoking cessation guidelines for health professionals : an update. Thorax, 55, 987-999). The forms of NRT currently available include nicotine chewing gum, several types of nicotine transdermal patches, nicotine nasal spray, nicotine inhalator, and several types of nicotine lozenges. They seem to have broadly similar effects. All of these products are only used after the user stopped smoking, and they contain explicit instructions to this effect. When NRT was first introduced in 1980s, there was a concern that if NRT IS used concurrently with smoking, this may lead to nicotine overdose. Since then, sufficient evidence has been generated to show this concern to be unfounded. Studies examining effect of NRT on ad lib smoking have shown no adverse effects of concurrent smoking and NRT use. We studied smokers smoking ad lib and using higher than usual doses of nicotine patches and found that this has no adverse effects on blood pressure and heart rate and no adverse subjective effects (Hajek, P. et al. (1991) Safety of wearing nicotine skin patches while smoking. Abstracts, 8th World Conference on Tobacco or Health, 251) The current invention is based on a notion that smokers smoke to self-administer nicotine and that smoking behaviour is maintained by its relationship with actions of nicotine on the brain. If nicotine is provided via an alternative route while the user still smokes, the link between smoking behaviour and central effects of nicotine is weakened. This can make the transition to stopping smoking easier, and alleviate withdrawal discomfort more effectively than if NRT is used only after the user stops smoking.
In addition to this, there is another mechanism, which can contribute to beneficial effects of pre-cessation use of nicotine replacement treatment. With most NRT products, users experience problems in getting used to local irritating effects and other side effects, and product under-use is very common. Many smoking cessation attempts fail because of this. This applies particularly to nicotine nasal spray, but also to the nicotine chewing gum and to other oral NRT products. Getting used to the NRT product and learning how to use it properly while they still smoking is a more effective and more forgiving way of initiating NRT use. This would lead to better use of NRT during cigarette abstinence and hence greater relief of withdrawal symptoms and a greater chance of maintaining abstinence. By the time users reach the quit day, they had time to habituate to product side effects and to acquire skills in its use, and so can benefit fully from it immediately.
We have tested some of these notions in an unpublished study and the results suggest that smokers pre-treated with nicotine transdermal patch for two weeks while smoking
<Desc/Clms Page number 2>
experience less withdrawal discomfort after smoking cessation than smokers who only started to wear the nicotine patch on the day they stopped smoking.
To provide details of the invention, it comprises provision of NRT prior to cessation of smoking.
NRT IS provided for a period of 1-4 weeks prior to smoking cessation though other duration is possible.
NRT is provided via transdermal nicotine patch or via any other nicotine replacement product, alone or In combination A recommended use is via gradually building up to full dally dose identical to the dose recommended in smoking cessation. E. g. for oral products, users start with a few doses per day and progress to using the product hourly. Patches are used once a day, starting with smaller size (lower delivery) patches and progressing to higher dose. Other dosing regimens are possible, including a dosing above that recommended for smoking cessation, and using a constant dose throughout the pre-quit period.
On cessation of smoking, NRT products are used as per labelling The following is one practical example of pre-cessation NRT use. During three weeks prior to quit date, smokers wear Nicorette small patch for the first 3 days, Nicorette medium patch for the next 4 days, and Nicorette large patch until the quit day and as long as required after that. One week prior to quit day smokers start using nicotine nasal spray, initially a few times a day, increasing the frequency of use as they habituate to the spray to one shot in each nostril per hour for at least the last three days prior to quit day. They continue to use nasal spray after the quit day for as long as required.
Other product combinations or single product use, and other duration of use and dosing regimens regarding pre-cessation NRT use are possible.

Claims (8)

  1. CLAIMS 1. The invention comprises provision of nicotine replacement treatment (NRT) prior to smoking cessation (quit day) to improve NRT efficacy
  2. 2. Provision of NRT as claimed in Claim 1 where NRT is nicotine transdermal patch
  3. 3. Provision of NRT as claimed in Claim 1 where NRT is nicotine chewing gum, nicotine lozenge, nicotine nasal spray, nicotine inhalator, nicotine sublingual lozenge, or nicotine in liquid form added to drinks.
  4. 4. Provision of NRT as claimed in Claim 1 where NRT is any other nicotine replacement product
  5. 5. Provision of NRT as claimed in Claim 1 where NRT is a combination of two or more NRT products, e. g nicotine transdermal patch and nicotine nasal spray
  6. 6. The method of Claim 1 further characterised in that NRT is administered for a period of 1-4 weeks prior to quit attempt
  7. 7. The method of Claim 1, wherein the daily NRT dose is either gradually increased over a period of days, or kept constant
  8. 8. The method of Claim 1, where NRT use IS continued after the quit date as per current practice
GB0115566A 2001-06-26 2001-06-26 Helping smokers stop Withdrawn GB2376884A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0115566A GB2376884A (en) 2001-06-26 2001-06-26 Helping smokers stop

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0115566A GB2376884A (en) 2001-06-26 2001-06-26 Helping smokers stop

Publications (2)

Publication Number Publication Date
GB0115566D0 GB0115566D0 (en) 2001-08-15
GB2376884A true GB2376884A (en) 2002-12-31

Family

ID=9917353

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0115566A Withdrawn GB2376884A (en) 2001-06-26 2001-06-26 Helping smokers stop

Country Status (1)

Country Link
GB (1) GB2376884A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011679A1 (en) * 1993-10-28 1995-05-04 Dynagen, Inc. Use of lobeline for the treatment of nicotine withdrawal
AU662877B3 (en) * 1993-10-21 1995-09-14 Amal Hakim Khalil Nicotine lozenges
US5721257A (en) * 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
EP1107730A2 (en) * 1998-09-03 2001-06-20 Jsr Llc Medicated chewing gum delivery system for nicotine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721257A (en) * 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
AU662877B3 (en) * 1993-10-21 1995-09-14 Amal Hakim Khalil Nicotine lozenges
WO1995011679A1 (en) * 1993-10-28 1995-05-04 Dynagen, Inc. Use of lobeline for the treatment of nicotine withdrawal
EP1107730A2 (en) * 1998-09-03 2001-06-20 Jsr Llc Medicated chewing gum delivery system for nicotine

Also Published As

Publication number Publication date
GB0115566D0 (en) 2001-08-15

Similar Documents

Publication Publication Date Title
Rose et al. Transdermal nicotine facilitates smoking cessation
Malhotra et al. Nicotine and periodontal tissues
US20030114475A1 (en) Methods for the treatment of addiction
Mendelsohn Optimising nicotine replacement therapy in clinical practice
Walsh et al. Treatment of tobacco use and dependence: the role of the dental professional
Nicita-Mauro et al. Non smoking for successful aging: therapeutic perspectives
Dale et al. Drug therapy to aid in smoking cessation: tips on maximizing patients' chances for success
Tonnesen et al. Recycling of hard-core smokers with nicotine nasal spray
Corelli et al. Medications for smoking cessation
WO2018169387A1 (en) Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction
WO2000018379A2 (en) Pharmaceutical preparation for use in a method to abate the use of tobacco by humans
GB2376884A (en) Helping smokers stop
Bolliger et al. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy
US9061052B2 (en) Aqueous extract of tobacco leaves, its uses in the treatment of dependence
Rosenberg An investigation into the effect on cigarette smoking of a new anti-smoking chewing gum
Agrawal et al. The medical management of Inpatients with tobacco dependency
Facts Smoking and Tobacco Use
AU2001284704B2 (en) Method for reducing or eliminating smoking
US20220175755A1 (en) Methods of treating tobacco smoking addiction, and treating nicotine and tobacco smoking addiction
Cooke Therapeutic advances in the treatment of cigarette addiction
SU1537259A1 (en) Agent for developing dislike to tobacco and tobacco fumes
Quigley et al. Smoking Cessation
Mazur et al. Can the use of varenicline improve the efficacy of pharmacotherapy for nicotine addiction?
RU2146942C1 (en) Method of treatment of tobacco smoking
US20040024028A1 (en) Method for reducing or eliminating smoking

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)